

Discordance between Oncotype DX Recurrence Score and RSPC for predicting residual risk of recurrence of ER-positive breast cancer

SUPPLEMENTARY DATA: Table S1.

Case and patient numbers in the study. Three patients each had two separate tumours or tumour foci concurrently submitted for Oncotype DX testing. Six cases from 6 patients were unsuitable for any further analysis (5 due to missing RS results, and 1 which was a self-funded test in a patient with two tumour-involved axillary lymph nodes). Nineteen further cases from 19 patients were unsuitable for analysis of treatment recommendation due to unavailable information regarding recommendation made.

	All Centres	Centre 1	Centre 2	Centre 3	Centre 4
<i>Entered into study</i>			<i>N (%)</i>		
cases	177 (100%)	39 (22.0%)	20 (11.3%)	94 (53.1%)	24 (13.6%)
patients	174 (100%)	37 (21.3%)	20 (11.5%)	94 (54%)	23 (13.2%)
<i>Analyses of concordances</i>			<i>N (%)</i>		
cases	171 (100%)	37 (21.6%)	20 (11.7%)	91 (53.2%)	23 (13.5%)
patients	168 (100%)	35 (20.8%)	20 (11.9%)	91 (54.2%)	22 (13.1%)
<i>Analyses of treatment recommendation</i>			<i>N (%)</i>		
cases	152 (100%)	37 (24.3%)	20 (13.2%)	73 (48.0%)	22 (14.5%)
patients	149 (100%)	35 (23.5%)	20 (13.4%)	73 (49.0%)	21 (14.1%)

TABLE S1.